Mini-Tumors grown in a dish could guide chemo choices for advanced colorectal cancer

NCT ID NCT06907342

Recruiting now Disease control Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether a lab-grown mini-tumor (tumouroid) from a patient's biopsy can help doctors pick the more effective chemotherapy between two standard options (FOLFOX or FOLFIRI) for metastatic colorectal cancer. The trial enrolls adults with a specific type of colorectal cancer that has spread and cannot be surgically removed. The main goal is to see if the tumouroid test can be completed quickly enough to guide first-line treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a lab-grown mini-tumor (tumouroid) test that guides whether to use FOLFOX or FOLFIRI chemotherapy
What this could lead to: If successful, this approach could make chemotherapy more effective and reduce side effects by matching each patient to the drug that works best for their unique tumor.
What could go wrong: This is a small, early feasibility study, so the test may not reliably predict which drug works best, and the approach may not improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORE NEEDLE BIOPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORE NEEDLE BIOPSY FIRST LINE TREATMENT METASTATIC COLORECTAL CANCER ORGANOIDS TUMOR, COLORECTAL TUMOROID

Contacts and locations

Show contact details

Locations

St. Olavs Hospital
RECRUITING

Trondheim, Norway

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.